381 related articles for article (PubMed ID: 24512308)
61. Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide.
Hajji N; Wallenborg K; Vlachos P; Füllgrabe J; Hermanson O; Joseph B
Oncogene; 2010 Apr; 29(15):2192-204. PubMed ID: 20118981
[TBL] [Abstract][Full Text] [Related]
62. E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors.
Jordaan G; Liao W; Sharma S
BMC Cancer; 2013 Feb; 13():88. PubMed ID: 23432814
[TBL] [Abstract][Full Text] [Related]
63. GATA-3-dependent Gene Transcription is Impaired upon HDAC Inhibition.
Geng X; Wang C; Abdelrahman S; Perera T; Saed B; Hu YS; Wolfe A; Reneau J; Murga-Zamalloa C; Wilcox RA
Clin Cancer Res; 2024 Mar; 30(5):1054-1066. PubMed ID: 38165708
[TBL] [Abstract][Full Text] [Related]
64. Histone deacetylases and epigenetic therapies of hematological malignancies.
Mercurio C; Minucci S; Pelicci PG
Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
[TBL] [Abstract][Full Text] [Related]
65. Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells.
Zhou Q; Dalgard CL; Wynder C; Doughty ML
BMC Neurosci; 2011 May; 12():50. PubMed ID: 21615950
[TBL] [Abstract][Full Text] [Related]
66. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
Thompson RC; Vardinogiannis I; Gilmore TD
PLoS One; 2013; 8(5):e62822. PubMed ID: 23667527
[TBL] [Abstract][Full Text] [Related]
67. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
Ferreira AC; Robaina MC; Rezende LM; Severino P; Klumb CE
Ann Hematol; 2014 Jun; 93(6):983-93. PubMed ID: 24577510
[TBL] [Abstract][Full Text] [Related]
68. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
Frew AJ; Lindemann RK; Martin BP; Clarke CJ; Sharkey J; Anthony DA; Banks KM; Haynes NM; Gangatirkar P; Stanley K; Bolden JE; Takeda K; Yagita H; Secrist JP; Smyth MJ; Johnstone RW
Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11317-22. PubMed ID: 18685088
[TBL] [Abstract][Full Text] [Related]
69. Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.
Chikamatsu K; Ishii H; Murata T; Sakakura K; Shino M; Toyoda M; Takahashi K; Masuyama K
Cancer Sci; 2013 Nov; 104(11):1468-75. PubMed ID: 23992541
[TBL] [Abstract][Full Text] [Related]
70. HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells.
Mazzio EA; Soliman KF
Cancer Genomics Proteomics; 2017 Jan; 14(1):17-33. PubMed ID: 28031235
[TBL] [Abstract][Full Text] [Related]
71. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
[TBL] [Abstract][Full Text] [Related]
72. Histone-deacetylase inhibitors for the treatment of cancer.
Lindemann RK; Gabrielli B; Johnstone RW
Cell Cycle; 2004 Jun; 3(6):779-88. PubMed ID: 15153801
[TBL] [Abstract][Full Text] [Related]
73. Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response.
Halsall JA; Turan N; Wiersma M; Turner BM
Epigenetics Chromatin; 2015; 8():29. PubMed ID: 26380582
[TBL] [Abstract][Full Text] [Related]
74. Histone deacetylase inhibitors and rational combination therapies.
Grant S; Dai Y
Adv Cancer Res; 2012; 116():199-237. PubMed ID: 23088872
[TBL] [Abstract][Full Text] [Related]
75. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
[TBL] [Abstract][Full Text] [Related]
76. Histone deacetylase (HDAC) activity is critical for embryonic kidney gene expression, growth, and differentiation.
Chen S; Bellew C; Yao X; Stefkova J; Dipp S; Saifudeen Z; Bachvarov D; El-Dahr SS
J Biol Chem; 2011 Sep; 286(37):32775-89. PubMed ID: 21778236
[TBL] [Abstract][Full Text] [Related]
77. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.
Ma T; Galimberti F; Erkmen CP; Memoli V; Chinyengetere F; Sempere L; Beumer JH; Anyang BN; Nugent W; Johnstone D; Tsongalis GJ; Kurie JM; Li H; Direnzo J; Guo Y; Freemantle SJ; Dragnev KH; Dmitrovsky E
Mol Cancer Ther; 2013 Aug; 12(8):1545-55. PubMed ID: 23686769
[TBL] [Abstract][Full Text] [Related]
78. Opposite effects of histone deacetylase inhibitors on glucocorticoid and estrogen signaling in human endometrial Ishikawa cells.
Rocha W; Sanchez R; Deschênes J; Auger A; Hébert E; White JH; Mader S
Mol Pharmacol; 2005 Dec; 68(6):1852-62. PubMed ID: 16186250
[TBL] [Abstract][Full Text] [Related]
79. A novel benzamine lead compound of histone deacetylase inhibitor ZINC24469384 can suppresses HepG2 cells proliferation by upregulating NR1H4.
Song Q; Li M; Fan C; Liu Y; Zheng L; Bao Y; Sun L; Yu C; Song Z; Sun Y; Wang G; Huang Y; Li Y
Sci Rep; 2019 Feb; 9(1):2350. PubMed ID: 30787420
[TBL] [Abstract][Full Text] [Related]
80. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
